Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MK-7965

Known as: CDK inhibitor SCH 727965 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Neuroblastoma (NB), the most common extracranial solid tumor of childhood, is responsible for approximately 15% of cancer-related… Expand
2015
2015
KRAS is activated by mutation in the vast majority of cases of pancreatic cancer; unfortunately, therapeutic attempts to inhibit… Expand
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2014
Highly Cited
2014
INTRODUCTION Effective therapies after failure of treatment with anthracyclines and taxanes are needed for patients with… Expand
Highly Cited
2014
Highly Cited
2014
OBJECTIVES Dinaciclib (MK-7965, formerly SCH 727965), a novel, small-molecule inhibitor of cyclin-dependent kinases, has been… Expand
Review
2014
Review
2014
Introduction: Cyclin-dependent kinases (CDK) represent attractive targets in oncology due to their key role in controlling gene… Expand
2013
2013
  • J. Stephensona, John Nemunaitisb, +9 authors Martin J. Edelmane
  • 2013
  • Corpus ID: 46988083
Objectives: Dinaciclib (MK-7965, formerly SCH 727965), a novel, small-molecule inhibitor of cyclindependent kinases, has been… Expand
  • table 2
  • figure 2
  • table 3
  • table 4
Highly Cited
2012
Highly Cited
2012
  • Malini Guha
  • Nature Reviews Drug Discovery
  • 2012
  • Corpus ID: 34625364
After more than a decade of clinical development for cancer and numerous failures, Phase III trials of cyclin-dependent kinase… Expand